MX2022009987A - Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23. - Google Patents

Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23.

Info

Publication number
MX2022009987A
MX2022009987A MX2022009987A MX2022009987A MX2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A
Authority
MX
Mexico
Prior art keywords
ulcerative colitis
antibody
safe
effective method
treating ulcerative
Prior art date
Application number
MX2022009987A
Other languages
English (en)
Inventor
Omoniyi Adedokun
Jewel Johanns
Katherine Li
Colleen Marano
Richard Strauss
Hongyan Zhang
Kimberly Shields-Tuttle
Christopher O''BRIEN
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2022009987A publication Critical patent/MX2022009987A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos y composiciones para el tratamiento clínico probado seguro y efectivo de la colitis ulcerosa, particularmente la colitis ulcerosa moderada a gravemente activa en pacientes que han tenido una respuesta inadecuada a o son intolerantes a una terapia convencional o existente por administración intravenosa y/o subcutánea de un anticuerpo anti-IL-12/IL-23p40.
MX2022009987A 2020-02-14 2021-02-12 Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23. MX2022009987A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062976582P 2020-02-14 2020-02-14
PCT/IB2021/051215 WO2021161270A2 (en) 2020-02-14 2021-02-12 Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody

Publications (1)

Publication Number Publication Date
MX2022009987A true MX2022009987A (es) 2022-11-10

Family

ID=77271772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009987A MX2022009987A (es) 2020-02-14 2021-02-12 Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23.

Country Status (11)

Country Link
US (2) US20210253690A1 (es)
EP (1) EP4103606A4 (es)
JP (1) JP2023514567A (es)
KR (1) KR20220141847A (es)
CN (1) CN115427444A (es)
AU (1) AU2021218265A1 (es)
BR (1) BR112022015996A2 (es)
CA (1) CA3170677A1 (es)
IL (1) IL295545A (es)
MX (1) MX2022009987A (es)
WO (1) WO2021161270A2 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205276A4 (en) * 2007-09-28 2012-08-15 Janssen Biotech Inc ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
RU2018113694A (ru) * 2015-09-17 2019-10-17 Эмджен Инк. Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
TWI744617B (zh) * 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法

Also Published As

Publication number Publication date
CA3170677A1 (en) 2021-08-19
KR20220141847A (ko) 2022-10-20
BR112022015996A2 (pt) 2022-10-11
CN115427444A (zh) 2022-12-02
AU2021218265A1 (en) 2022-10-06
EP4103606A4 (en) 2024-04-10
WO2021161270A2 (en) 2021-08-19
US20210253690A1 (en) 2021-08-19
WO2021161270A9 (en) 2022-03-24
JP2023514567A (ja) 2023-04-06
IL295545A (en) 2022-10-01
EP4103606A2 (en) 2022-12-21
US20240002494A1 (en) 2024-01-04
WO2021161270A3 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
MX2021003411A (es) Metodo seguro y eficaz para tratar la colitis ulcerosa con el anticuerpo anti-il12/il23.
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MX2020006650A (es) Esketamina para el tratamiento de la depresión.
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
WO2013062959A3 (en) Continuous subcutaneous administration of interferon-alpha to hepatitis b infected patients
MX2022009987A (es) Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23.
MX2022013923A (es) Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23.
MX2023004017A (es) Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23.
MX2022004581A (es) Método seguro y eficaz para tratar la colitis ulcerosa con el anticuerpo anti-il12/il23.
EA202290027A1 (ru) Способы и композиции для улучшения результатов лечения пациентов с раком
MX2021013910A (es) Metodos para administrar un anticuerpo anti-cd38 para tratar el mieloma multiple.
WO2017123667A3 (en) Non-ischemic heart failure treatment by cell therapy
Zhang et al. Intraoperative tumor lysis-induced fatal hyperkalemia
Zhang et al. Clinical observation on acupuncture treatment for post-stroke spastic hemiplegia
MX2015014939A (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
RU2010107158A (ru) Способ лечения экомодифицированного атопического дерматита у детей, проживающих в условиях воздействия техногенных химических факторов
MX2022016174A (es) Composiciones y metodos para tratar un trastorno obsesivo-compulsivo.
Craig et al. Outcomes of acellular dermal matrix for immediate tissue expander reconstruction with radiotherapy
MX2022010437A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
Fuerst Yoga Benefits Lung Cancer Patients & Their Caregivers
EA202190858A1 (ru) Безопасный и эффективный способ лечения язвенного колита с помощью антител к il-12/il-23
MA55140B1 (fr) Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il12/il23
ZA202201633B (en) Compositions and methods for treating cancer
CA3177260A1 (en) Endoxifen for the treatment of bipolar i disorder